Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Novo Nordisk's Wegovy weight-loss drug approved in China



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 5-Novo Nordisk's Wegovy weight-loss drug approved in China</title></head><body>

Added comment from Raffles Hospital Beijing marketing manager and Novo Nordisk

By Andrew Silver

SHANGHAI, June 25 (Reuters) -Novo Nordisk's NOVOb.CO hugely popular weight-loss drug Wegovy has been approved in China, it said on Tuesday, the world's second-largest economy and the country estimated to hold the highest number of overweight or obese people.

The company will communicate details on pricing and availability when it launches, it told Reuters in a statement. Novo said in March it would initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug.

Raffles Hospital Beijing, a major hospital in the Chinese capital, might place an order around September, but concrete timing is uncertain, Rose Niu Wei, a marketing manager at the private hospital, told Reuters.

By 1000 GMT on Tuesday Novo's shares were up 1.5%, having earlier touched record highs that valued the company at nearly $490 billion.

The number of overweight adults in China, the world's second most populous country, is projected to reach 540 million by 2030, 2.8 times higher than 2000 levels, a Chinese public health study showed in 2020. Numbers who are obese are seen jumping 7.5 times to 150 million.

But Novo may have a much shorter time in the Chinese market to make the most of its early-mover advantage in weight-loss drugs.

Its patent on semaglutide, the key ingredient in Wegovy and its diabetes drug Ozempic, is set to expire in less than two years in China compared to in 2031 in Europe and Japan and in 2032 in the U.S, and local drugmakers are racing to develop generic or biosimilar versions.

Novo is also in the midst of a legal fight in China over the patent, an adverse ruling in which could make it lose its semaglutide exclusivity even sooner. That would make China the first major market where it is stripped of patent protection for the drugs.

Booming demand for Wegovy has propelled Novo's shares to record highs, and the company last year overtook LVMH LVMH.PA to become Europe's most valuable listed company.

But its success has left Novo facing shortages and forced to limit the number of patients taking the once-weekly injection.

"At the moment capacity and not global demand is the main limit on how fast (sales volumes) can grow, and adding a huge Chinese market will only increase the need for more capacity," said Allan von Mehren, China economist at Danske Bank.

"It is hard to say how fast volumes can go up, but the potential should be big."

The group faces competition from rival Eli Lilly LLY.N, whose diabetes drug tirzepatide received approval from China in May. Some analysts expect Zepound, the U.S. firm's weight-loss drug with the same active ingredient, will be approved in China this year or in the first half of 2025.

Both Eli Lilly and Novo are racing to increase production in a weight-loss market estimated to reach at least $100 billion globally by the decade's end. Both companies' obesity treatments belong to a class of drugs originally developed for diabetes known as GLP-1 agonists.

Novo announced on Monday a $4.1 billion investment to build a U.S. facility to fill injection pens for Wegovy and Ozempic.

Ozempic won approval from China in 2021, and Novo saw sales of the drug in the greater China region double to 4.8 billion Danish crowns ($698 million) last year.

At least two Chinese firms, Livzon Pharmaceutical Group 000513.SZ and Hangzhou Jiuyuan Gene Engineering, have already applied to begin commercial sales of Ozempic copies.

Shares in Livzon finished unchanged, while major Jiuyuan Gene shareholder Huadong Medicine 000963.SZ closed down 0.3%.



Wegovy sales propel Novo Nordisk shares https://tmsnrt.rs/4eCpkXm


Reporting by Andrew Silver; Editing by Tomasz Janowski, Miyoung Kim, Edwina Gibbs and Jan Harvey

</body></html>

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.